Xenon Pharmaceuticals - Common Shares (XENE) closed at $37.75 on November 18, 2026, down 2.7% from the previous close, on volume of 1,192,446 shares (30-day average 1,312,285).
Data as of November 18, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 11, 2026 | Call Spread | 21-Jan-2840 : 60 C | 230 |
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 18, 2026. See the largest for 5, 30, 60 and 90 days
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks (Tue, 17-Nov 8:50 AM ET)
Xenon Pharmaceuticals Earnings Call Signals Broad Pipeline Momentum
TipRanks (Sat, 14-Nov 11:25 PM ET)
Xenon Reports Q3 2026 Financial Results and Provides Business Update
Globe Newswire (Mon, 9-Nov 4:01 PM ET)
Xenon to Present at Upcoming Investor Conferences
Globe Newswire (Tue, 3-Nov 4:01 PM ET)
Xenon to Report Q3 2026 Financial Results on November 9, 2026
Globe Newswire (Mon, 2-Nov 4:01 PM ET)
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Fri, 30-Oct 4:01 PM ET)
Globe Newswire (Thu, 29-Oct 8:30 AM ET)
Wolf Popper LLP Continues Investigation on Behalf of Xenon Pharmaceuticals Inc. Investors
Globe Newswire (Tue, 20-Oct 8:50 PM ET)
XENE Investors Have Opportunity to Join Xenon Pharmaceuticals Inc. Fraud Investigation with SBS Law
Business Wire (Wed, 23-Sep 12:23 AM ET)
PRNewswire (Tue, 22-Sep 6:18 PM ET)
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
Xenon Pharmaceuticals - Common Shares trades on the NASDAQ stock market under the symbol XENE.
As of November 19, 2026, XENE stock price declined to $37.56 with 1,205,458 million shares trading.
XENE has a beta of 0.23, meaning it tends to be less sensitive to market movements. XENE has a correlation of 0.00 to the broad based SPY ETF.
XENE has a market cap of $3.69 billion. This is considered a Mid Cap stock.
In the last 3 years, XENE traded as high as $72.66 and as low as $26.74.
The top ETF exchange traded funds that XENE belongs to (by Net Assets): IWM, TCAF, IWO, IBB, VTWO.
XENE has underperformed the market in the last year with a return of -7.5%, while the SPY ETF gained +9.6%. In the last 3 month period, XENE fell short of the market, returning -40.6%, while SPY returned -6.5%. However, in the most recent 2 weeks XENE has outperformed the stock market by returning -4.2%, while SPY returned -6.6%.
XENE support price is $36.86 and resistance is $38.64 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that XENE shares will trade within this expected range on the day.